Small cell carcinoma of the prostate treated with amrubicin

Abstract

We describe the use of amrubicin hydrochloride to treat small cell carcinoma of the prostate in a 23-year-old man. Initial radiological examinations of the patient revealed a pelvic tumor associated with bilateral hydronephrosis, pelvic lymph node swelling, and lumbar vertebral bone metastases. The pathological diagnosis was small cell carcinoma originating in the prostate, based on positive immunohistochemical staining for neuron-specific enolase, synaptophysin, and myoglobulin; and negative staining for CD3e, CD20, leukocyte common antigen, and CD99. The clinical stage was T4N1M1. A bilateral nephrostomy was performed to improve renal function, and an ileostomy was established to prevent ileus. The first induction chemotherapy consisted of amrubicin 35 mg/m(2) (days 1, 2, 3, monthly). The amrubicin regimen caused a dramatic reduction in tumor size, but could not be continued, because of the occurrence of grade 4 diarrhea. A different regimen was then administered, consisting of one cycle of a 50% dose and a second cycle of a 75% dose of etoposide (100 mg/m(2) days 1, 2, 3), coadministered with carboplatin (AUC 5, plasma concentration curve). Five months after the induction of chemotherapy, the patient suffered respiratory arrest and died.

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate

“…One of the above-mentioned studies applied second-line therapy with cisplatin and etoposide after progression to the first-line treatment with carboplatin and docetaxel [3]. Combination therapy of doxorubicin, cyclophosphamide and vincristine [9] as well as amrubicin monotherapy [23] showed some activity in small case series. Molecular alterations in NEPCs have been extensively studied.…”

Amrubicin is effective against small cell carcinoma of the prostate as a second‐line chemotherapeutic agent: A case report

“…More cycles of AMR may be considered when SCCP progression appears based on reports demonstrating the feasibility of repeated AMR administration . To date, eight patients with SCCP received second‐line chemotherapy with AMR (Table ), and their mean survival time was longer (20.4 months) than that reported for conventional therapies. Tumor volume reduction of 74% has been achieved with AMR .…”

“…To date, eight patients with SCCP received second‐line chemotherapy with AMR (Table ), and their mean survival time was longer (20.4 months) than that reported for conventional therapies. Tumor volume reduction of 74% has been achieved with AMR . And for the patient, AMR was covered by Japanese national health insurance.…”

“…However, these therapies have limited efficacy against SCCP . Some recent reports have shown that second‐line chemotherapy with AMR is effective against SCCP. Herein, we report a case where AMR was effective against SCCP as a second‐line chemotherapeutic agent.…”

Effective treatment of relapsed prostate small cell carcinoma with amrubicin: report of a case

“…AMR was the only regimen reported as the 2nd regimen alone. Table 1 shows a summary of reports of AMR treatment of SCCP [5,[11][12][13]. AMR was administrated as 2nd line regimen, except No.3 case.…”